Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407456 | 0.87 | EPHX2 (0.34) | HSD11B1PKML3MBTL1EPHX2 | |
| SCHEMBL5409968 | 0.80 | EPHX2 (0.33) | PKMEPHX2 | |
| SCHEMBL24274069 | 0.78 | ABL1 (0.36) | HSD11B1L3MBTL1EPHX2CNR2 | |
| SCHEMBL6999213 | 0.78 | — | — | |
| SCHEMBL8581404 | 0.71 | — | — | |
| SCHEMBL8581708 | 0.71 | — | — | |
| SCHEMBL8584647 | 0.71 | — | — | |
| SCHEMBL28845132 | 0.71 | HSD11B1 (0.56) | HSD11B1PKML3MBTL1CNR2 | |
| SCHEMBL16593601 | 0.71 | HSD11B1 (0.56) | HSD11B1PKML3MBTL1CNR2 | |
| SCHEMBL18799647 | 0.71 | HSD11B1 (0.56) | HSD11B1PKML3MBTL1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2021262426-A9 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021262426-A9 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021262426-A2 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262426-A2 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-1081150-B1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | DAICEL CHEM (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6486330-B1 | 4-oxatricyclo[4.3.1.1 3,8]undecan-5-one derivative and process for producing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1081150-A1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | HSD11B1 2165/4885PKM 4800/4885L3MBTL1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.